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Standardized serologic tests for Lyme disease are needed, as isolationi or in situ demonistra-
tioin of the spirochete has proved difficult. At thie Ceniters for Disease Conitrol (CDC), anl in-
direct immunofluorescence assay (IFA) was modified from a previously described IFA, and an
enizyme-linked immnunosorbent assay (ELISA) was developed with soluble spirochetal anl-
tigens. Both tests were evaluated with sera from Lyme disease patielnts, nlormal colntrols, anld
patients with otlher diseases. They were hliglhly specific for Lyme disease wheni sera from pa-
tients witlh syphilis were excluded. Sensitivity varied with disease stage: for patienits with
erythema chronicum migrans alone, the IFA was 53 percenit sensitive anld tlle ELISA was 67
percent sensitive. In contrast, all patients witlh complicated Lyme disease had at least onie
serum specimeni positive in both tests. Twenty-six percent of the sera from 289 patienits with
suspected Lyme disease that were submitted to CDC in 1983 had IFA titers >256 and thus
were considered positive. Both tests slhould be useful diagnostic anid epidemiologic aids.
Indirect immunofluorescence assays (IFAs) have been used to show that sera from
patients with Lyme disease often have antibodies that bind to spirochetes isolated
from Ixodes damminiticks [1,2]. Peak IgM titers occur three to six weeks after onset
of erythema chronicum migrans (ECM), with a geometric mean titer (GMT) of 178;
peak IgG titers with a GMT of641 occur months later in sera from patients with ar-
thritis [2]. IgG and occasionally IgM titers tend to persist for at least several years in
patients with recurrent attacks of arthritis. The potential usefulness of antibody
determinations in diagnosing Lyme disease was noted [1,2].
At the Centers for Disease Control (CDC), we standardized an IFA and evaluated
an enzyme-linked immunosorbent assay (ELISA) as serodiagnostic aids for Lyme
disease [3]. We showed that, with reasonable precautions, either test could be used
with a high degree of sensitivity and specificity for diagnosis of complicated Lyme
disease.
TEST METHODOLOGY
The IFA used at CDC (Appendix I) differs in several ways from the one described
by Steere et al. [2]. First, we used an acetone-fixed, whole-cell antigen prepared
from strain B31 (from Barbour) instead of an antigen fixed by freezing. Titers ob-
tained with the acetone-fixed antigen compared favorably with those against the
frozen antigen. Second, we made the initial 1:16 serum dilution in 3 percent normal
hen's yolk sac suspension to remove nonspecific background fluorescence that can
otherwise interfere with determining fluorescence endpoints. Finally, we used a
fluorescein isothiocyanate (FITC)-labeled antihuman immunoglobulin (polyvalent)
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All rights of reproductioni in anly form reserved.conjugate instead of anti-IgM and anti-IgG conjugates. To insure adequate test
specificity, a titer >256 was selected as the cutoff level for a positive test result.
The ELISA was developed with a soluble antigen obtained from strain B31 by
sonication and an antihuman alkaline phosphatase-labeled Fab, which binds to all
immunoglobulin classes (Appendix II). Because optical density (OD) readings can
show between-run variation, a high-titered serum was used as an internal positive
control in each run. The ratio of the OD of the test serum to the OD of the control
serum was determined. A ratio >0.41, which corresponded to 22 standard devia-
tions above the mean OD ratio of 100 normal control sera, was considered a positive
test result. Each serum was tested in duplicate at a 1:500 dilution.
EVALUATION OF THE IFA AND ELISA
A total of 138 sera from 45 patients with Lyme disease were generously provided
by Allen C. Steere, M.D., and were tested with the IFA and ELISA. Sera from 39
patients were positive in each test, for an overall sensitivity estimate of 87 percent.
All 30 patients with cardiac, neuritic, or arthritic complications had positive Lyme
serologic results by both tests; in contrast, of 15 patients with ECM alone, only eight
(53 percent) and ten (67 percent) had positive test results by IFA and ELISA, respec-
tively (Table 1). Not all sera drawn from each patient with complications showed
positive serologic results. Of the 77 sera drawn from the 30 patients with com-
plicated Lyme disease, 73 (95 percent) had IFA titers . 256, and 75 (97 percent) had
ELISA OD ratios .0.41.
To determine whether the timing of the serum specimen influenced the low sen-
sitivity of the tests on sera drawn during the ECM stage, we determined the mean
day of illness from onset to serum collection for patients with active ECM: 23 days
vs. 19 days for positive and negative IFA results, and 21 days vs. 21 days for positive
and negative ELISA results. Therefore, the stage of the disease, instead of the tim-
ing of the serum specimen, appeared to be the more important determinant of test
sensitivity. Similarly, only 27 percent of the patients with ECM alone showed
seroconversion by IFA (at least fourfold increase in titer to . 256), but 60 percert of
the patients with complicated cases showed seroconversion. Of added interest was
the observation that 86 percent of the sera drawn from seven patients while they
were in remission from ECM but before complications developed, had positive IFA
titers (vs. 56 percent of the ECM patients in whom complications never developed);
100 percent of the sera from the seven patients in remission (vs. 67 percent who had
no subsequent disease) had positive ELISA results.
To estimate test specificity, IFA titers and ELISA OD ratios were determined on
sera from 106 patients with similar clinical manifestations, related etiologic agents,
TABLE 1
Reactivity of Sera from Lyme Disease Patients Against Lyme
Spirochetal Antigens
No. (0) with Positive Test
Disease No. of ___________
Stage Patients IFA ELISA
ECM 15 8 ( 53) 10 ( 67)
Complications 30 30 (100) 30 (100)
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TABLE 2
Reactivity of Sera from Well Persons or Patients with Other Diseases
Against Lyme Spirochetal Antigens
No. with Positive Test
Disease No. of
Categorya Sera IFA ELISA
Not ill 100 0 4
SLE, RA 32 2 0
RMSF 15 0 0
LD 20 0 0
Lepto 11 0 0
Trep 28 15 9
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aAbbreviations: SLE, systemic lupus erythematosus; RA, rheuma-
toid arthritis; RMSF, Rocky Mountain spotted fever; LD, Legion-
naires' disease; Lepto, leptospirosis; Trep, treponemal diseases
(syphilis, yaws, and pinta).
or possible cross-reactive antigens (e.g., legionellosis). The only significant cross-
reactions were observed with sera from patients with treponemal diseases (Table 2).
The IFA was 97 percent specific if these sera were excluded and 84 percent if they
were included in the analysis. Similarly, the ELISA was 100 percent specific if the
treponemal sera were excluded and 92 percent if they were included. Also shown in
Table 2 but not included in the specificity estimates are test results on sera from 100
individuals who were not ill. Further experiments showed that using the Reiter im-
munosorbent, which is used routinely to lower nonspecific fluorescent treponemal
antibody (FTA) titers, also lowered Lyme-specific titers to an unacceptable level.
However, syphilis patients could be differentiated from Lyme disease patients with
the rapid reagin card test (RPR screening test) or the microhemagglutination
(MHA-TP) confirmatory test. Sera from Lyme disease patients gave negative test
results in the two tests for syphilis.
EFFECT OF IMMUNOGLOBULIN CLASS, SPIROCHETE STRAIN,
AND CUTOFF LEVELS
The major flaw in the serologic tests developed so far for Lyme disease is low test
sensitivity for patients with ECM alone. Preliminary experiments designed to im-
prove sensitivity by changing the antigen strain, conjugate, or cutofflevel failed. We
and others [2] found that spirochetal strains isolated from different sources, in-
cluding tick and human, gave the same serologic results when they were used as
IFA antigens for human serum titrations. Lowering the cutoff level for a positive
test result gave minimal improvement in sensitivity, whereas the specificity was
lowered by 9 percent for ELISA and 10 percent for IFA. A comparison of IFA titers
obtained with class-specific conjugates and the polyvalent conjugate showed that
serologic reactivity was primarily due to IgG during complicated Lyme disease,
whereas IgM contributed more to the reaction during ECM. This is in agreement
with Steere's observations [2]. In our study, titers with the polyvalent conjugate were
the same or slightly greater than titers obtained with monovalent conjugates.
Therefore, routinely using conjugates specific for IgG or IgM offered no apparent
advantage.HAZEL W. WILKINSON
FUTURE USE
In 1983, CDC began testing serum specimens submitted through state health
laboratories from patients with suspected Lyme disease. By late summer, we had
determined IFA titers for 289 patients from 38 states (excluding sera obtained in
special surveys). Seventy-four (26 percent) had titers .256. As expected, the
preponderance of sera were submitted from states known to be endemic for the
disease: Massachusetts, New Jersey, Minnesota, and Maryland. Data are being
analyzed for the entire 1983 tick season, and the preliminary analyses suggest that
Lyme disease may be occurring more widely than has been previously appreciated.
All but two (Eastsouth Central and Westsouth Central) ofnine U.S. regions submit-
ted at least one positive serum sample. The place of exposure of these patients must
still be determined. Because of the difficulty in culturing the spirochete and
demonstrating its presence in tissue, serologic testing will be relied on heavily as an
aid in diagnosing the disease and also in estimating disease prevalence. Of the two
tests developed for this purpose, the ELISA has several advantages over the IFA:
greater sensitivity during the ECM stage, less subjective readings, potential for
automation, and the possibility of using a purified, specific antigen. Efforts are in
progress to further improve the ELISA for routine use.
APPENDIX I
Indirect immunofluorescence assay (IFA) for Lyme disease [3]
1. Grow spirochetes in suitable medium, such as BSK [4] for five to seven
days.
2. Harvest cells by centrifugation at 21,000 g, 15°C, for 30 minutes.
3. Wash cells three times in 0.01 M phosphate-buffered saline, pH 7.2 (PBS).
4. Dilute cells in PBS to yield approximately 100 organisms per 40 x
microscopic field.
5. Apply antigen suspension to glass slides and allow to air-dry. It is conve-
nient to use acetone-resistant multiwell fluorescent antibody slides. Place
20 1l of antigen in each well, and remove excess liquid with a Pasteur
pipette. After the slide has dried, fix in acetone for 10 minutes and allow to
air-dry.
6. For each serum to be tested, prepare twofold dilutions in PBS from an ini-
tial 1:16 dilution in 3 percent normal hen's yolk sac suspension (NYS). The
NYS decreases nonspecific fluorescence that interferes with reading end-
points.
7. Place a drop (20 Al) of each serum dilution . 1:64 on an antigen-coated
well. Incubate in a moist chamber for 30 minutes at 37°C.
8. Rinse slides, then soak them in PBS for 10 minutes. Blot dry.
9. Place a drop (20 1l) of FITC-labeled antihuman immunoglobulin (Ig)
(polyvalent conjugate) on each well. Incubate, rinse, and dry as above.
Alternatively, use Ig class-specific conjugates, but only if class-specificity
has been evaluated.
10. Cover slides with carbonate-buffered mounting fluid, pH 9, and coverslips.
11. Read fluorescence intensity on a fluorescence microscope equipped for
fluorescein. At CDC, the titer is expressed as the reciprocal of the highest
dilution of serum giving 1 + (barely visible) blue-green fluorescence of at
least 50 percent of the spirochetes per microscopic field. We use a Leitz
Dialux 20 fluorescence microscope equipped with an HBO-100 mercury in-
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cident light source, I cube filter system, 40 x dry objective, and 6.3 x
binoculars (final magnification, 315 x).1
12. A titer .256 is considered a positive test result.
APPENDIX II
Enzyme-linked immunosorbent assay (ELISA) for Lyme disease [3]
1. Grow spirochetes in suitable medium, such as BSK [4], for five to seven
days. For the ELISA, approximately 350 ml of broth medium is required.
2. Harvest cells by centrifugation at 21,000 g, 15°C, for 30 minutes.
3. Wash cells three times in 0.01 M phosphate-buffered saline, pH 7.2 (PBS).
4. Resuspend washed cells in 15 ml of PBS and mix with an equal volume of
2M NaCl in PBS.
5. Sonicate the suspension in an ice bath for 10 minutes at 60 percent ofmaxi-
mum setting on a Biosonik IV Sonifier (or comparable settings on different
models).'
6. Centrifuge sonicate at 21,000 g, 4°C, for 30 minutes.
7. Wash sediment once with 5 ml of 1 M NaCl. Pool both supernatant fluids
and dialyze against several changes ofdistilled water and then against PBS.
8. Determine protein concentration ofantigen, and adjust its concentration to
5 ug of protein per ml of 0.1 M carbonate buffer, pH 9.6.
9. Place 25 Al of antigen in each well of a U-bottom microtiter plate
(Dynatech, Cambridge, MA).' Incubate overnight at 4°C.
10. Wash plate three times with 0.9 percent NaCl containing 0.05 percent
Tween 20 and 0.02 percent NaN3.
11. To each well, add 25 1l of a 1:500 dilution of test serum in PBS containing
Tween 20 and 0.02 percent NaN3 (PBS-TA). Incubate at 37°C for one
hour.
12. Wash plate three times as above.
13. To each well, add 25 p41 of antihuman immunoglobulin alkaline
phosphatase conjugate, diluted in PBS-TA. Incubate at 37°C for three
hours and wash as before.
14. To each well, add 25 A1 of p-nitrophenyl phosphate substrate (2 mg/ml in
0.05 M carbonate buffer, pH 9.8, containing 0.001 M MgCl2). Incubate at
37°C for one hour.
15. To stop the reaction, add 25 Al of 5 N NaOH to each well. Read OD at 405
nm.
16. At CDC, the ratio of the OD of the test serum to the OD of a high-titered
serum from a patient with Lyme disease is determined (OD ratio). An OD
ratio > 0.41 (> .2 SDs above the mean OD ratio of 100 normal control sera)
is considered a positive test result. Results are expressed as the mean of
duplicate tests.
'Use of trade name is for identificationi only and does not imply enidorsemenit by the Public Health Ser-
vice or by the U.S. Department of Health and Humani Services.
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